Cargando…
Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk
Increased understanding of the Wnt signaling pathway has led to the development of romosozumab, one of the most potent osteoanabolic agents to date for osteoporosis treatment. Romosozumab is a monoclonal antibody that inhibits sclerostin, a natural inhibitor of the Wnt signaling pathway. Romosozumab...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511529/ https://www.ncbi.nlm.nih.gov/pubmed/36154750 http://dx.doi.org/10.1177/17455057221125577 |